Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO) (HY286296)

Name: Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO)
Brand: abinScience
SKU: HY286296
Price: 370 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HY286296
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG
ID de clon	BSI-001
Actividad biológica	BSI-001 binds strongly to BT-474 and SK-BR-3 cells with overexpressed HER2 [1]. BSI-001 (100 nM, serially diluted; 3-6 days) exerts weak inhibitory effects on the proliferation of HER2-positive cancer cells when used alone, but it exerts potent synergistic anti-proliferative effects in multiple HER2-positive cancer cell lines when combined with Trastuzumab () at a fixed dose ratio of 1:1 [1]. BSI-001 (72 h) potently inhibits the migration of BT-474 cells when combined with Trastuzumab [1]. BSI-001 (100 nM; 72 h) = induces late-stage apoptosis and PARP cleavage in BT-474 cells when combined with Trastuzumab [1]. BSI-001 (100 nM; 3 days) reduces the total HER2 protein level in BT-474 cells and inhibits HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab [1]. . In combination with Trastuzumab, showed substantially enhanced BT-474 cell proliferation inhibition compared to single agents. Showed stronger synergism between 5G9 and trastuzumab. In SK-BR-3, AU-565, and NCI-N87 cells, the combination of 5G9 and trastuzumab reduced cell viability more effectively. Apoptosis Analysis [1] Cell Line: HER2-positive human breast cancer BT-474 cells Concentration: 100 nM Incubation Time: 72 h Result: Resulted in a significantly lower number of viable BT-474 cells and a higher level of late-stage apoptosis combinated with Trastuzumab, compared to the trastuzumab-pertuzumab combination.
Objetivo	CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P04626
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	BSI-001, BSI001, BSI001
Fondo	Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu).
Referencias	1. Ding X, et al. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. EBioMedicine. 2020 Oct;60:102996. [HY286296]
Nota	For research use only. Not suitable for clinical or therapeutic use.